Hurtado-de-Mendoza Alejandra, Reyna Valerie F, Wolfe Christopher R, Gómez-Trillos Sara, Sutton Arnethea L, Brennan Ashleigh, Sheppard Vanessa B
Department of Oncology, Georgetown University Medical Center, Washington, DC, USA.
Jess and Mildred Fisher Center for Hereditary Cancer and Clinical Cancer Genomics, Washington, DC, USA.
Prev Med Rep. 2022 Jul 5;28:101887. doi: 10.1016/j.pmedr.2022.101887. eCollection 2022 Aug.
Minorities at increased risk for Hereditary Breast and Ovarian Cancer (HBOC) frequently have low awareness and use of genetic counseling and testing (GCT). Making sure that evidence-based interventions (EBIs) reach minorities is key to reduce disparities. is a theory-informed EBI that has been proven to be efficacious in mostly non-Hispanic White non-clinical populations. We conducted formative work to inform adaptations of for use in clinical settings with at-risk diverse women.
Genetic counselors (n = 20) were recruited nationally; at-risk Latinas and Blacks (n = 21) were recruited in Washington DC and Virginia. They completed the EBI between April 2018 - September 2019. Participants completed an acceptability scale and an interview to provide suggestions about implementation adaptations. T-tests for independent samples compared acceptability between at-risk women and genetic counselors. The Consensual Qualitative Research Framework was used to code adaptation suggestions. Suggested adaptations were discussed by a multidisciplinary team to integrate fidelity and adaptation considerations.
At-risk women had a significantly higher acceptability ( = 4.17, = 0.47 vs. = 3.24, = 0.64; = 0.000; scale 1-5) and satisfaction scores ( = 8.3, = 1.3 vs. = 4.2, = 2.0; = 0.000; scale 1-10) than genetic counselors. Genetic counselors and at-risk women suggested contextual (e.g. format) and content (e.g. shortening) adaptations to enhance the fit of for diverse clinical populations.
Findings illustrate the process of integrating fidelity and adaptation considerations to ensure that EBIs retain their core components while enhancing the fit to minoritized clinical populations. Future studies will test the efficacy of the adapted in a Randomized Controlled Trial.
遗传性乳腺癌和卵巢癌(HBOC)风险增加的少数族裔对遗传咨询和检测(GCT)的知晓率和使用率通常较低。确保基于证据的干预措施(EBI)能够惠及少数族裔是减少差距的关键。[干预措施名称]是一种基于理论的EBI,已被证明在主要为非西班牙裔白人的非临床人群中有效。我们开展了形成性工作,以指导[干预措施名称]在有风险的不同女性临床环境中的应用调整。
在全国范围内招募了20名遗传咨询师;在华盛顿特区和弗吉尼亚州招募了21名有风险的拉丁裔和黑人。他们在2018年4月至2019年9月期间完成了[干预措施名称]EBI。参与者完成了一份可接受性量表和一次访谈,以提供关于实施调整的建议。独立样本t检验比较了有风险女性和遗传咨询师之间的可接受性。采用共识定性研究框架对调整建议进行编码。一个多学科团队讨论了建议的调整,以综合保真度和适应性考虑。
有风险的女性的可接受性(均值 = 4.17,标准差 = 0.47,而遗传咨询师均值 = 3.24,标准差 = 0.64;t = <0.000;量表1 - 5)和满意度得分(均值 = 8.3,标准差 = 1.3,而遗传咨询师均值 = 4.2,标准差 = 2.0;t = <0.000;量表1 - 10)显著高于遗传咨询师。遗传咨询师和有风险的女性建议进行背景(如形式)和内容(如缩短)调整,以提高[干预措施名称]对不同临床人群的适用性。
研究结果说明了综合保真度和适应性考虑的过程,以确保EBI在保留其核心成分的同时,提高对少数族裔临床人群的适用性。未来的研究将在随机对照试验中测试调整后的[干预措施名称]的疗效。